PEA (Palmitoylethanolamide): Research, Dosing, and Where to Buy in 2026
A research-first profile for PEA (Palmitoylethanolamide) (palmitoylethanolamide, PEA), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
PEA (Palmitoylethanolamide) is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 2 transcript dosing protocols for PEA (Palmitoylethanolamide), each linked to its source.
- Also indexed as palmitoylethanolamide, PEA.
- 2 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is PEA (Palmitoylethanolamide)?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
PEA (Palmitoylethanolamide) Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Andrew Williams | The KPV Masterclass | Complete User's Guide (2026) | 00:34:55 | Andrew Williams reported using 300 to 600 mg PEA per day as mast cell stabilizer support. | anecdotal |
| The Hunter Williams Podcast | The KPV Masterclass | Complete User's Guide (2026) | 00:34:55 | Speaker 1 reported using 300 to 600 mg per day, paired with KPV, for perceived mast cell and digestive support. | anecdotal |
Where to Buy PEA (Palmitoylethanolamide) in 2026
No tracked vendor recommendations for PEA (Palmitoylethanolamide) yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about PEA (Palmitoylethanolamide). Each line links to the original source.
- "PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001)." · Lang-Illievich K et al, 2023 PubMed
Research and Studies
8 PubMed-indexed papers reference PEA (Palmitoylethanolamide). Top 8 shown.
Legal Status
PEA (Palmitoylethanolamide) is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is PEA (Palmitoylethanolamide) FDA-approved?
PEA (Palmitoylethanolamide) is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for PEA (Palmitoylethanolamide)?
This page aggregates 2 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on PEA (Palmitoylethanolamide)?
8 PubMed-indexed paper(s) reference PEA (Palmitoylethanolamide) in our current research feed. See the Research and Studies section above for citations.